NYSE:MRKPharmaceuticals
Is Long-Term GARDASIL Protection Data Reframing The Vaccine Investment Case For Merck (MRK)?
Earlier in March, Merck & Co., Inc. announced it would present new clinical and real-world data at EUROGIN 2026 showing that its GARDASIL 9 and GARDASIL HPV vaccines maintained effectiveness for at least 14 and up to 18 years against certain HPV-related cancers and diseases in women aged 16 to 26 at vaccination.
By highlighting extended real-world protection across multiple countries and HPV-related conditions, these data could strengthen confidence among healthcare systems in long-term HPV...